Public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination among US adults aged 18-49 years at increased risk for severe RSV disease. - Singer D; La EM; Dubois de Gennes C; Graham J; Grace M; Biundo E; Verelst F (Vaccine, 2026)